A citation-based method for searching scientific literature


List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
100

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
100

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
100

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K McGuire, Weichung J Shih, Francesco Cosentino, Bernard Charbonnel, David Z I Cherney, Samuel Dagogo-Jack, Richard Pratley, Michelle Greenberg, Shuai Wang, Susan Huyck,[...]. JAMA Cardiol 2021
109
100

Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Massar Omar, Jesper Jensen, Mulham Ali, Peter H Frederiksen, Caroline Kistorp, Lars Videbæk, Mikael Kjær Poulsen, Christian D Tuxen, Sören Möller, Finn Gustafsson,[...]. JAMA Cardiol 2021
14
50

Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes.
Jamie L Benham, Jane E Booth, Ronald J Sigal, Stella S Daskalopoulou, Alexander A Leung, Doreen M Rabi. Int J Cardiol Heart Vasc 2021
4
50

A Review of the Molecular Mechanisms Underlying the Development and Progression of Cardiac Remodeling.
Leonardo Schirone, Maurizio Forte, Silvia Palmerio, Derek Yee, Cristina Nocella, Francesco Angelini, Francesca Pagano, Sonia Schiavon, Antonella Bordin, Albino Carrizzo,[...]. Oxid Med Cell Longev 2017
157
50

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
50

The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Hsiang-Chun Lee, Yi-Lin Shiou, Shih-Jie Jhuo, Chia-Yuan Chang, Po-Len Liu, Wun-Jyun Jhuang, Zen-Kong Dai, Wei-Yu Chen, Yun-Fang Chen, An-Sheng Lee. Cardiovasc Diabetol 2019
53
50

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis.
Javed Butler, Muhammad Shariq Usman, Muhammad Shahzeb Khan, Stephen J Greene, Tim Friede, Muthiah Vaduganathan, Gerasimos Filippatos, Andrew J Stewart Coats, Stefan D Anker. ESC Heart Fail 2020
19
50

Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE).
Atsushi Tanaka, Itaru Hisauchi, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Hirofumi Tomiyama, Masataka Sata, Shinichiro Ueda, Jun-Ichi Oyama, Masafumi Kitakaze,[...]. ESC Heart Fail 2020
21
50

Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study.
Jonas Oldgren, Sanna Laurila, Axel Åkerblom, Aino Latva-Rasku, Eleni Rebelos, Henrik Isackson, Maria Saarenhovi, Olof Eriksson, Kerstin Heurling, Edvin Johansson,[...]. Diabetes Obes Metab 2021
4
50

Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.
Daobo Li, Yingying Liu, Tesfaldet Habtemariam Hidru, Xiaolei Yang, Yunsong Wang, Cheng Chen, Ka Hou Christien Li, Yuqi Tang, Yushan Wei, Gary Tse,[...]. Front Endocrinol (Lausanne) 2021
4
50


Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial.
Mie K Eickhoff, Flemming J Olsen, Marie Frimodt-Møller, Lars J Diaz, Jens Faber, Magnus T Jensen, Peter Rossing, Frederik Persson. J Diabetes Complications 2020
4
50

Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
Muhammad Shahzeb Khan, G Michael Felker, Ileana L Piña, Alexander Camacho, Devavrat Bapat, Nasrien E Ibrahim, Alan S Maisel, Margaret F Prescott, Jonathan H Ward, Scott D Solomon,[...]. JACC Heart Fail 2021
8
50

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
Qingmiao Shao, Lei Meng, Sharen Lee, Gary Tse, Mengqi Gong, Zhiwei Zhang, Jichao Zhao, Yungang Zhao, Guangping Li, Tong Liu. Cardiovasc Diabetol 2019
54
50

Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction.
Jasper Tromp, B Daan Westenbrink, Wouter Ouwerkerk, Dirk J van Veldhuisen, Nilesh J Samani, Piotr Ponikowski, Marco Metra, Stefan D Anker, John G Cleland, Kenneth Dickstein,[...]. J Am Coll Cardiol 2018
105
50

Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction.
Kim A Connelly, Yanling Zhang, Aylin Visram, Andrew Advani, Sri N Batchu, Jean-François Desjardins, Kerri Thai, Richard E Gilbert. JACC Basic Transl Sci 2019
39
50

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena Čelutkienė, Ovidiu Chioncel,[...]. Eur Heart J 2021
139
50

Luseogliflozin: first global approval.
Anthony Markham, Shelley Elkinson. Drugs 2014
50
50


The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study.
Salvatore Carbone, Hayley E Billingsley, Justin M Canada, Edoardo Bressi, Brando Rotelli, Dinesh Kadariya, Dave L Dixon, Roshanak Markley, Cory R Trankle, Richard Cooke,[...]. Diabetes Metab Res Rev 2020
11
50

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Carlos G Santos-Gallego, Ariana P Vargas-Delgado, Juan Antonio Requena-Ibanez, Alvaro Garcia-Ropero, Donna Mancini, Sean Pinney, Frank Macaluso, Samantha Sartori, Merce Roque, Fernando Sabatel-Perez,[...]. J Am Coll Cardiol 2021
63
50

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.
Alexander J M Brown, Stephen Gandy, Rory McCrimmon, John Graeme Houston, Allan D Struthers, Chim C Lang. Eur Heart J 2020
38
50

Unresolved issues in left ventricular postischemic remodeling and progression to heart failure.
Edoardo Gronda, Stefania Sacchi, Giuditta Benincasa, Emilio Vanoli, Claudio Napoli. J Cardiovasc Med (Hagerstown) 2019
10
50



Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis.
Sean McGrath, XiaoFei Zhao, Russell Steele, Brett D Thombs, Andrea Benedetti. Stat Methods Med Res 2020
56
50

Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
Alberto Aimo, Hanna K Gaggin, Andrea Barison, Michele Emdin, James L Januzzi. JACC Heart Fail 2019
37
50

Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial.
Jagdeep S S Singh, Ify R Mordi, Keeran Vickneson, Amir Fathi, Peter T Donnan, Mohapradeep Mohan, Anna Maria J Choy, Stephen Gandy, Jacob George, Faisel Khan,[...]. Diabetes Care 2020
36
50

Epigenetics in heart failure phenotypes.
Alexander Berezin. BBA Clin 2016
30
50

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Carlos G Santos-Gallego, Juan Antonio Requena-Ibanez, Rodolfo San Antonio, Kiyotake Ishikawa, Shin Watanabe, Belen Picatoste, Eduardo Flores, Alvaro Garcia-Ropero, Javier Sanz, Roger J Hajjar,[...]. J Am Coll Cardiol 2019
172
50


Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients - A Randomized Controlled Trial.
Hiroyuki Kayano, Shinji Koba, Tsutomu Hirano, Taiju Matsui, Hiroto Fukuoka, Hiroaki Tsuijita, Shigeto Tsukamoto, Toshiyuki Hayashi, Tsutomu Toshida, Norikazu Watanabe,[...]. Circ J 2020
4
50

Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.
Kentaro Ejiri, Toru Miyoshi, Hajime Kihara, Yoshiki Hata, Toshihiko Nagano, Atsushi Takaishi, Hironobu Toda, Seiji Nanba, Yoichi Nakamura, Satoshi Akagi,[...]. J Am Heart Assoc 2020
9
50

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
736
50

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Eur Heart J 2016
50

Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.
Chi Young Shim, Jiwon Seo, Iksung Cho, Chan Joo Lee, In-Jeong Cho, Purevjargal Lhagvasuren, Seok-Min Kang, Jong-Won Ha, Gyoonhee Han, Yangsoo Jang,[...]. Circulation 2021
14
50

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, Kenneth Mangion, Giles Roditi, Ross T Campbell, Colin Berry, Victor Chong, Liz Coyle, Kieran F Docherty,[...]. Circulation 2021
59
50

A systematic review identifies a lack of standardization in methods for handling missing variance data.
Natasha Wiebe, Ben Vandermeer, Robert W Platt, Terry P Klassen, David Moher, Nicholas J Barrowman. J Clin Epidemiol 2006
149
50

Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
Lin Shi, Diqi Zhu, Shoubao Wang, Aixia Jiang, Fen Li. Am J Hypertens 2019
21
50

Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.
Nazha Hamdani, Sarah Costantino, Andreas Mügge, Djamel Lebeche, Carsten Tschöpe, Thomas Thum, Francesco Paneni. Eur Heart J 2021
5
50



Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett,[...]. Circulation 2019
168
50

Epigenetic Therapies for Heart Failure: Current Insights and Future Potential.
Claudio Napoli, Paola Bontempo, Vittorio Palmieri, Enrico Coscioni, Ciro Maiello, Francesco Donatelli, Giuditta Benincasa. Vasc Health Risk Manag 2021
2
50

Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus.
Dimitrios Patoulias, Christodoulos Papadopoulos, Alexandra Katsimardou, Maria-Styliani Kalogirou, Michael Doumas. Am J Cardiol 2020
3
50

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
560
50

Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea).
Eun Sil Koh, Kyungdo Han, You-Seon Nam, Eric T Wittbrodt, Peter Fenici, Mikhail N Kosiborod, Hiddo J L Heerspink, Soon-Jib Yoo, Hyuk-Sang Kwon. Diabetes Obes Metab 2021
4
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.